APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
-2.89%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.01B
AUM Growth
+$3.01B
(-30%)
Cap. Flow
-$880M
Cap. Flow
% of AUM
-29.21%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
22
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$97.9M |
| 2 |
Becton Dickinson
BDX
|
$71.3M |
| 3 |
Zoetis
ZTS
|
$67.8M |
| 4 |
Merck
MRK
|
$63.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$61.9M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$218M |
| 2 |
argenx
ARGX
|
$128M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$125M |
| 4 |
Boston Scientific
BSX
|
$120M |
| 5 |
Neurocrine Biosciences
NBIX
|
$97.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arrowhead Research
ARWR
$3.84B
| $44.2M | 1.47% |
1,741,300
+366,300
| +27% | +$9.3M |
|
27
Pacific Biosciences
PACB
$378M
| $44.1M | 1.47% |
+3,812,600
| New | +$44.1M |
|
|
28
Boston Scientific
BSX
$159B
| $42.5M | 1.41% |
850,000
-2,406,700
| -74% | -$120M |
|
29
Axsome Therapeutics
AXSM
$6.09B
| $38.2M | 1.27% |
619,200
-50,800
| -8% | -$3.13M |
|
30
Vir Biotechnology
VIR
$765M
| $38.2M | 1.27% |
1,640,200
+790,200
| +93% | +$18.4M |
|
31
Immunocore
IMCR
$1.78B
| $38.1M | 1.26% |
769,800
-384,200
| -33% | -$19M |
|
32
Karyopharm Therapeutics
KPTI
$61.4M
| $37.5M | 1.24% |
9,633,911
| – | – |
|
33
Abbott
ABT
$230B
| $35.8M | 1.19% |
+354,000
| New | +$35.8M |
|
34
Biogen
BIIB
$20.8B
| $35.8M | 1.19% |
+128,800
| New | +$35.8M |
|
|
BLU
35
DELISTED
BELLUS Health Inc.
BLU
| $32.8M | 1.09% |
4,553,577
-46,421
| -1% | -$334K |
|
36
Icon
ICLR
$14B
| $30.5M | 1.01% |
142,900
-72,100
| -34% | -$15.4M |
|
37
BioMarin Pharmaceuticals
BMRN
$11.3B
| $29.2M | 0.97% |
+300,575
| New | +$29.2M |
|
38
Revolution Medicines
RVMD
$7.43B
| $29.1M | 0.97% |
1,344,800
-1,130,200
| -46% | -$24.5M |
|
39
89bio
ETNB
$1.37B
| $28.1M | 0.93% |
+1,842,976
| New | +$28.1M |
|
40
Amylyx Pharmaceuticals
AMLX
$877M
| $26.4M | 0.88% |
+900,000
| New | +$26.4M |
|
41
CureVac
CVAC
$1.21B
| $24.7M | 0.82% |
+3,550,000
| New | +$24.7M |
|
42
Avantor
AVTR
$8.74B
| $23.8M | 0.79% |
+1,125,000
| New | +$23.8M |
|
|
NSTG
43
DELISTED
NanoString Technologies, Inc.
NSTG
| $21.9M | 0.73% |
2,217,000
+159,800
| +8% | +$1.58M |
|
|
FUSN
44
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $21.5M | 0.71% |
+5,700,000
| New | +$21.5M |
|
45
Rocket Pharmaceuticals
RCKT
$358M
| $21.3M | 0.71% |
1,244,400
-282,687
| -19% | -$4.84M |
|
46
Kezar Life Sciences
KZR
$28.5M
| $20.4M | 0.68% |
6,519,400
-263,000
| -4% | -$823K |
|
47
Biohaven
BHVN
$1.71B
| $20.3M | 0.67% |
1,487,200
-4,800
| -0.3% | -$65.6K |
|
48
Cencora
COR
$57.2B
| $20.3M | 0.67% |
+126,600
| New | +$20.3M |
|
49
Mineralys Therapeutics
MLYS
$1.94B
| $19.8M | 0.66% |
+1,263,800
| New | +$19.8M |
|
|
VERV
50
DELISTED
Verve Therapeutics
VERV
| $19.5M | 0.65% |
1,351,700
-213,300
| -14% | -$3.08M |
|